SCHEMBL3985667

SCHEMBL3985667

CC(=O)c1nn(Cc2ccc(F)c(Cl)c2)c(=O)c2c(OCc3ccccc3)c3n(c12)CCN(C)C3=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 1/20 0.39
PTGER4 P35408 1/20 0.36
FSCN1 Q16658 1/20 0.35
CYP2C9 P11712 1/20 0.35
PPARG P37231 1/20 0.35
DRD4 P21917 1/20 0.34
ALDH1A1 P00352 6/20 0.34
GAA P10253 2/20 0.34
PKM P14618 1/20 0.34
PREP P48147 1/20 0.34
MAPT P10636 3/20 0.34
LMNA P02545 2/20 0.34
TSHR P16473 2/20 0.34
KDM5A P29375 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
POLB P06746 1/20 0.33
HTT P42858 3/20 0.33
KCNJ6 P48051 2/20 0.33
KCNJ5 P48544 2/20 0.33
KCNJ3 P48549 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3987007 0.93 SCD (0.38) SCDPTGER4FSCN1CYP2C9PPARG
SCHEMBL3983623 0.90 SCD (0.38) SCDPTGER4FSCN1CYP2C9PPARG
SCHEMBL3985345 0.89 SCD (0.37) SCDPTGER4FSCN1DRD4GRM2
SCHEMBL3983704 0.86 SCD (0.36) SCDPTGER4FSCN1DRD4ALDH1A1
SCHEMBL3987232 0.85 PTGER4 (0.35) PTGER4FSCN1CYP2C9PPARGPREP
SCHEMBL3985359 0.82 SCD (0.33) SCDDRD4
SCHEMBL4746270 0.81 SCD (0.40) SCDFSCN1DRD4ALDH1A1HTT
SCHEMBL4750000 0.81 FSCN1 (0.43) SCDFSCN1DRD4PREPSMN1; SMN2
SCHEMBL3982263 0.80 SMN1; SMN2 (0.40) CYP2C9ALDH1A1PKMMAPTLMNA
SCHEMBL3982232 0.79 ALDH1A1 (0.38) ALDH1A1LMNAPOLBHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
EP-1756114-A2 HIV INTEGRASE INHIBITORS Merck and Co., Inc. (US) 2007-02-28 EP disclosed
WO-2005110414-A2 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287394-A1 Hiv Integrase Inhibitors DHPS, DPYD, TYMP SCD 2672/4885PTGER4 2608/4885FSCN1 4865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.